Summary

The global Anti-CD47 Antibody market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
An Anti-CD47 Antibody is a type of antibody that targets the CD47 protein, which is overexpressed in various types of cancer cells. CD47 acts as a "don"t eat me" signal, preventing the immune system"s macrophages from engulfing and destroying cancer cells. The Anti-CD47 Antibody works by blocking the CD47 protein, thereby allowing the immune system to recognize and eliminate cancer cells effectively. This antibody has shown promise as a potential therapeutic agent in cancer immunotherapy, as it enhances the body"s natural immune response against cancer while minimizing toxic side effects.
The industry trend of Anti-CD47 Antibody is highly promising and gaining significant attention in the field of cancer research and drug development. Several pharmaceutical companies and research institutions are actively pursuing the development of Anti-CD47 Antibody-based therapies. There is a growing interest in combining this antibody with other immuno-oncology agents, such as checkpoint inhibitors, to enhance its therapeutic efficacy. Clinical trials evaluating the safety and efficacy of Anti-CD47 Antibody treatments in various cancer types are ongoing and showing encouraging results. The advancement of precision medicine and personalized cancer therapies further supports the potential of Anti-CD47 Antibody as a valuable addition to the oncology treatment armamentarium.
The global Anti-CD47 Antibody market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
BosterBio
Leinco Technologies
Bioss
Novus Biologicals
Thermo Fisher Scientific
Biorbyt
Abbexa
Bio X Cell
GeneTex
R&D Systems
LSBio
MyBioSource
ProSci
antibodies-online
ABclonal Technology
Abnova Corporation
G Biosciences
BioLegend
Bio-Rad
Huabio
BPS Bioscience
OriGene Technologies
St John's Laboratory
Absolute Antibody
NSJ Bioreagents
Cell Signaling Technology
RayBiotech
Beijing Solarbio Science & Technology
Bethyl Laboratories
Abeomics
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Anti-CD47 Antibody market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Anti-CD47 Antibody value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-CD47 Antibody Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Anti-CD47 Antibody Market Share by Revenue, by Region (2021-2026)
2.4 Global Anti-CD47 Antibody Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Anti-CD47 Antibody Market Size and Prospective (2021-2032)
2.5.2 Europe Anti-CD47 Antibody Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Anti-CD47 Antibody Market Size and Prospective (2021-2032)
2.5.4 Latin America Anti-CD47 Antibody Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Anti-CD47 Antibody Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Anti-CD47 Antibody Historical Market Size by Type (2021-2026)
3.2 Global Anti-CD47 Antibody Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Anti-CD47 Antibody
4 Breakdown Data by Application
4.1 Global Anti-CD47 Antibody Historical Market Size by Application (2021-2026)
4.2 Global Anti-CD47 Antibody Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Anti-CD47 Antibody Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Anti-CD47 Antibody Players by Revenue (2021-2026)
5.1.2 Global Anti-CD47 Antibody Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Anti-CD47 Antibody Revenue
5.4 Global Anti-CD47 Antibody Market Concentration Analysis
5.4.1 Global Anti-CD47 Antibody Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Anti-CD47 Antibody Revenue in 2025
5.5 Global Key Players of Anti-CD47 Antibody Head Offices and Areas Served
5.6 Global Key Players of Anti-CD47 Antibody, Product and Application
5.7 Global Key Players of Anti-CD47 Antibody, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Anti-CD47 Antibody Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Anti-CD47 Antibody Market Size by Type (2021-2026)
6.1.2.2 North America Anti-CD47 Antibody Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Anti-CD47 Antibody Market Size by Application (2021-2026)
6.1.3.2 North America Anti-CD47 Antibody Market Share by Application (2021-2026)
6.1.4 North America Anti-CD47 Antibody Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Anti-CD47 Antibody Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Anti-CD47 Antibody Market Size by Type (2021-2026)
6.2.2.2 Europe Anti-CD47 Antibody Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Anti-CD47 Antibody Market Size by Application (2021-2026)
6.2.3.2 Europe Anti-CD47 Antibody Market Share by Application (2021-2026)
6.2.4 Europe Anti-CD47 Antibody Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Anti-CD47 Antibody Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Anti-CD47 Antibody Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Anti-CD47 Antibody Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Anti-CD47 Antibody Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Anti-CD47 Antibody Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Anti-CD47 Antibody Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Anti-CD47 Antibody Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Anti-CD47 Antibody Market Size by Type (2021-2026)
6.4.2.2 Latin America Anti-CD47 Antibody Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Anti-CD47 Antibody Market Size by Application (2021-2026)
6.4.3.2 Latin America Anti-CD47 Antibody Market Share by Application (2021-2026)
6.4.4 Latin America Anti-CD47 Antibody Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Anti-CD47 Antibody Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Anti-CD47 Antibody Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Anti-CD47 Antibody Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Anti-CD47 Antibody Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Anti-CD47 Antibody Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Anti-CD47 Antibody Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 BosterBio
7.1.1 BosterBio Company Details
7.1.2 BosterBio Business Overview
7.1.3 BosterBio Anti-CD47 Antibody Introduction
7.1.4 BosterBio Revenue in Anti-CD47 Antibody Business (2021-2026)
7.1.5 BosterBio Recent Development
7.2 Leinco Technologies
7.2.1 Leinco Technologies Company Details
7.2.2 Leinco Technologies Business Overview
7.2.3 Leinco Technologies Anti-CD47 Antibody Introduction
7.2.4 Leinco Technologies Revenue in Anti-CD47 Antibody Business (2021-2026)
7.2.5 Leinco Technologies Recent Development
7.3 Bioss
7.3.1 Bioss Company Details
7.3.2 Bioss Business Overview
7.3.3 Bioss Anti-CD47 Antibody Introduction
7.3.4 Bioss Revenue in Anti-CD47 Antibody Business (2021-2026)
7.3.5 Bioss Recent Development
7.4 Novus Biologicals
7.4.1 Novus Biologicals Company Details
7.4.2 Novus Biologicals Business Overview
7.4.3 Novus Biologicals Anti-CD47 Antibody Introduction
7.4.4 Novus Biologicals Revenue in Anti-CD47 Antibody Business (2021-2026)
7.4.5 Novus Biologicals Recent Development
7.5 Thermo Fisher Scientific
7.5.1 Thermo Fisher Scientific Company Details
7.5.2 Thermo Fisher Scientific Business Overview
7.5.3 Thermo Fisher Scientific Anti-CD47 Antibody Introduction
7.5.4 Thermo Fisher Scientific Revenue in Anti-CD47 Antibody Business (2021-2026)
7.5.5 Thermo Fisher Scientific Recent Development
7.6 Biorbyt
7.6.1 Biorbyt Company Details
7.6.2 Biorbyt Business Overview
7.6.3 Biorbyt Anti-CD47 Antibody Introduction
7.6.4 Biorbyt Revenue in Anti-CD47 Antibody Business (2021-2026)
7.6.5 Biorbyt Recent Development
7.7 Abbexa
7.7.1 Abbexa Company Details
7.7.2 Abbexa Business Overview
7.7.3 Abbexa Anti-CD47 Antibody Introduction
7.7.4 Abbexa Revenue in Anti-CD47 Antibody Business (2021-2026)
7.7.5 Abbexa Recent Development
7.8 Bio X Cell
7.8.1 Bio X Cell Company Details
7.8.2 Bio X Cell Business Overview
7.8.3 Bio X Cell Anti-CD47 Antibody Introduction
7.8.4 Bio X Cell Revenue in Anti-CD47 Antibody Business (2021-2026)
7.8.5 Bio X Cell Recent Development
7.9 GeneTex
7.9.1 GeneTex Company Details
7.9.2 GeneTex Business Overview
7.9.3 GeneTex Anti-CD47 Antibody Introduction
7.9.4 GeneTex Revenue in Anti-CD47 Antibody Business (2021-2026)
7.9.5 GeneTex Recent Development
7.10 R&D Systems
7.10.1 R&D Systems Company Details
7.10.2 R&D Systems Business Overview
7.10.3 R&D Systems Anti-CD47 Antibody Introduction
7.10.4 R&D Systems Revenue in Anti-CD47 Antibody Business (2021-2026)
7.10.5 R&D Systems Recent Development
7.11 LSBio
7.11.1 LSBio Company Details
7.11.2 LSBio Business Overview
7.11.3 LSBio Anti-CD47 Antibody Introduction
7.11.4 LSBio Revenue in Anti-CD47 Antibody Business (2021-2026)
7.11.5 LSBio Recent Development
7.12 MyBioSource
7.12.1 MyBioSource Company Details
7.12.2 MyBioSource Business Overview
7.12.3 MyBioSource Anti-CD47 Antibody Introduction
7.12.4 MyBioSource Revenue in Anti-CD47 Antibody Business (2021-2026)
7.12.5 MyBioSource Recent Development
7.13 ProSci
7.13.1 ProSci Company Details
7.13.2 ProSci Business Overview
7.13.3 ProSci Anti-CD47 Antibody Introduction
7.13.4 ProSci Revenue in Anti-CD47 Antibody Business (2021-2026)
7.13.5 ProSci Recent Development
7.14 antibodies-online
7.14.1 antibodies-online Company Details
7.14.2 antibodies-online Business Overview
7.14.3 antibodies-online Anti-CD47 Antibody Introduction
7.14.4 antibodies-online Revenue in Anti-CD47 Antibody Business (2021-2026)
7.14.5 antibodies-online Recent Development
7.15 ABclonal Technology
7.15.1 ABclonal Technology Company Details
7.15.2 ABclonal Technology Business Overview
7.15.3 ABclonal Technology Anti-CD47 Antibody Introduction
7.15.4 ABclonal Technology Revenue in Anti-CD47 Antibody Business (2021-2026)
7.15.5 ABclonal Technology Recent Development
7.16 Abnova Corporation
7.16.1 Abnova Corporation Company Details
7.16.2 Abnova Corporation Business Overview
7.16.3 Abnova Corporation Anti-CD47 Antibody Introduction
7.16.4 Abnova Corporation Revenue in Anti-CD47 Antibody Business (2021-2026)
7.16.5 Abnova Corporation Recent Development
7.17 G Biosciences
7.17.1 G Biosciences Company Details
7.17.2 G Biosciences Business Overview
7.17.3 G Biosciences Anti-CD47 Antibody Introduction
7.17.4 G Biosciences Revenue in Anti-CD47 Antibody Business (2021-2026)
7.17.5 G Biosciences Recent Development
7.18 BioLegend
7.18.1 BioLegend Company Details
7.18.2 BioLegend Business Overview
7.18.3 BioLegend Anti-CD47 Antibody Introduction
7.18.4 BioLegend Revenue in Anti-CD47 Antibody Business (2021-2026)
7.18.5 BioLegend Recent Development
7.19 Bio-Rad
7.19.1 Bio-Rad Company Details
7.19.2 Bio-Rad Business Overview
7.19.3 Bio-Rad Anti-CD47 Antibody Introduction
7.19.4 Bio-Rad Revenue in Anti-CD47 Antibody Business (2021-2026)
7.19.5 Bio-Rad Recent Development
7.20 Huabio
7.20.1 Huabio Company Details
7.20.2 Huabio Business Overview
7.20.3 Huabio Anti-CD47 Antibody Introduction
7.20.4 Huabio Revenue in Anti-CD47 Antibody Business (2021-2026)
7.20.5 Huabio Recent Development
7.21 BPS Bioscience
7.21.1 BPS Bioscience Company Details
7.21.2 BPS Bioscience Business Overview
7.21.3 BPS Bioscience Anti-CD47 Antibody Introduction
7.21.4 BPS Bioscience Revenue in Anti-CD47 Antibody Business (2021-2026)
7.21.5 BPS Bioscience Recent Development
7.22 OriGene Technologies
7.22.1 OriGene Technologies Company Details
7.22.2 OriGene Technologies Business Overview
7.22.3 OriGene Technologies Anti-CD47 Antibody Introduction
7.22.4 OriGene Technologies Revenue in Anti-CD47 Antibody Business (2021-2026)
7.22.5 OriGene Technologies Recent Development
7.23 St John's Laboratory
7.23.1 St John's Laboratory Company Details
7.23.2 St John's Laboratory Business Overview
7.23.3 St John's Laboratory Anti-CD47 Antibody Introduction
7.23.4 St John's Laboratory Revenue in Anti-CD47 Antibody Business (2021-2026)
7.23.5 St John's Laboratory Recent Development
7.24 Absolute Antibody
7.24.1 Absolute Antibody Company Details
7.24.2 Absolute Antibody Business Overview
7.24.3 Absolute Antibody Anti-CD47 Antibody Introduction
7.24.4 Absolute Antibody Revenue in Anti-CD47 Antibody Business (2021-2026)
7.24.5 Absolute Antibody Recent Development
7.25 NSJ Bioreagents
7.25.1 NSJ Bioreagents Company Details
7.25.2 NSJ Bioreagents Business Overview
7.25.3 NSJ Bioreagents Anti-CD47 Antibody Introduction
7.25.4 NSJ Bioreagents Revenue in Anti-CD47 Antibody Business (2021-2026)
7.25.5 NSJ Bioreagents Recent Development
7.26 Cell Signaling Technology
7.26.1 Cell Signaling Technology Company Details
7.26.2 Cell Signaling Technology Business Overview
7.26.3 Cell Signaling Technology Anti-CD47 Antibody Introduction
7.26.4 Cell Signaling Technology Revenue in Anti-CD47 Antibody Business (2021-2026)
7.26.5 Cell Signaling Technology Recent Development
7.27 RayBiotech
7.27.1 RayBiotech Company Details
7.27.2 RayBiotech Business Overview
7.27.3 RayBiotech Anti-CD47 Antibody Introduction
7.27.4 RayBiotech Revenue in Anti-CD47 Antibody Business (2021-2026)
7.27.5 RayBiotech Recent Development
7.28 Beijing Solarbio Science & Technology
7.28.1 Beijing Solarbio Science & Technology Company Details
7.28.2 Beijing Solarbio Science & Technology Business Overview
7.28.3 Beijing Solarbio Science & Technology Anti-CD47 Antibody Introduction
7.28.4 Beijing Solarbio Science & Technology Revenue in Anti-CD47 Antibody Business (2021-2026)
7.28.5 Beijing Solarbio Science & Technology Recent Development
7.29 Bethyl Laboratories
7.29.1 Bethyl Laboratories Company Details
7.29.2 Bethyl Laboratories Business Overview
7.29.3 Bethyl Laboratories Anti-CD47 Antibody Introduction
7.29.4 Bethyl Laboratories Revenue in Anti-CD47 Antibody Business (2021-2026)
7.29.5 Bethyl Laboratories Recent Development
7.30 Abeomics
7.30.1 Abeomics Company Details
7.30.2 Abeomics Business Overview
7.30.3 Abeomics Anti-CD47 Antibody Introduction
7.30.4 Abeomics Revenue in Anti-CD47 Antibody Business (2021-2026)
7.30.5 Abeomics Recent Development
8 Anti-CD47 Antibody Market Dynamics
8.1 Anti-CD47 Antibody Industry Trends
8.2 Anti-CD47 Antibody Market Drivers
8.3 Anti-CD47 Antibody Market Challenges
8.4 Anti-CD47 Antibody Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Anti-CD47 Antibody Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Anti-CD47 Antibody Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Anti-CD47 Antibody Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Anti-CD47 Antibody Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Anti-CD47 Antibody Revenue Share by Region (2021-2026)
Table 6. Global Anti-CD47 Antibody Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Anti-CD47 Antibody Revenue Share Forecast by Region (2027-2032)
Table 8. Global Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Anti-CD47 Antibody Market Share by Revenue, by Type (2021-2026)
Table 10. Global Anti-CD47 Antibody Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Anti-CD47 Antibody Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Anti-CD47 Antibody Market Share by Revenue, by Application (2021-2026)
Table 15. Global Anti-CD47 Antibody Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Anti-CD47 Antibody Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Anti-CD47 Antibody Applications
Table 18. Global Anti-CD47 Antibody Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Anti-CD47 Antibody Market Share by Players (2021-2026)
Table 20. Global Top Anti-CD47 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD47 Antibody as of 2025)
Table 21. Ranking of Global Top Anti-CD47 Antibody Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Anti-CD47 Antibody Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Anti-CD47 Antibody, Headquarters and Area Served
Table 24. Global Key Players of Anti-CD47 Antibody, Product and Application
Table 25. Global Key Players of Anti-CD47 Antibody, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Anti-CD47 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Anti-CD47 Antibody Market Share by Revenue, by Company (2021-2026)
Table 29. North America Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Anti-CD47 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Anti-CD47 Antibody Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Anti-CD47 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Anti-CD47 Antibody Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Anti-CD47 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Anti-CD47 Antibody Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Anti-CD47 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Anti-CD47 Antibody Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Anti-CD47 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Anti-CD47 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 47. BosterBio Company Details
Table 48. BosterBio Business Overview
Table 49. BosterBio Anti-CD47 Antibody Product
Table 50. BosterBio Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 51. BosterBio Recent Development
Table 52. Leinco Technologies Company Details
Table 53. Leinco Technologies Business Overview
Table 54. Leinco Technologies Anti-CD47 Antibody Product
Table 55. Leinco Technologies Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 56. Leinco Technologies Recent Development
Table 57. Bioss Company Details
Table 58. Bioss Business Overview
Table 59. Bioss Anti-CD47 Antibody Product
Table 60. Bioss Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 61. Bioss Recent Development
Table 62. Novus Biologicals Company Details
Table 63. Novus Biologicals Business Overview
Table 64. Novus Biologicals Anti-CD47 Antibody Product
Table 65. Novus Biologicals Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 66. Novus Biologicals Recent Development
Table 67. Thermo Fisher Scientific Company Details
Table 68. Thermo Fisher Scientific Business Overview
Table 69. Thermo Fisher Scientific Anti-CD47 Antibody Product
Table 70. Thermo Fisher Scientific Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 71. Thermo Fisher Scientific Recent Development
Table 72. Biorbyt Company Details
Table 73. Biorbyt Business Overview
Table 74. Biorbyt Anti-CD47 Antibody Product
Table 75. Biorbyt Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 76. Biorbyt Recent Development
Table 77. Abbexa Company Details
Table 78. Abbexa Business Overview
Table 79. Abbexa Anti-CD47 Antibody Product
Table 80. Abbexa Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 81. Abbexa Recent Development
Table 82. Bio X Cell Company Details
Table 83. Bio X Cell Business Overview
Table 84. Bio X Cell Anti-CD47 Antibody Product
Table 85. Bio X Cell Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 86. Bio X Cell Recent Development
Table 87. GeneTex Company Details
Table 88. GeneTex Business Overview
Table 89. GeneTex Anti-CD47 Antibody Product
Table 90. GeneTex Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 91. GeneTex Recent Development
Table 92. R&D Systems Company Details
Table 93. R&D Systems Business Overview
Table 94. R&D Systems Anti-CD47 Antibody Product
Table 95. R&D Systems Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 96. R&D Systems Recent Development
Table 97. LSBio Company Details
Table 98. LSBio Business Overview
Table 99. LSBio Anti-CD47 Antibody Product
Table 100. LSBio Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 101. LSBio Recent Development
Table 102. MyBioSource Company Details
Table 103. MyBioSource Business Overview
Table 104. MyBioSource Anti-CD47 Antibody Product
Table 105. MyBioSource Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 106. MyBioSource Recent Development
Table 107. ProSci Company Details
Table 108. ProSci Business Overview
Table 109. ProSci Anti-CD47 Antibody Product
Table 110. ProSci Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 111. ProSci Recent Development
Table 112. antibodies-online Company Details
Table 113. antibodies-online Business Overview
Table 114. antibodies-online Anti-CD47 Antibody Product
Table 115. antibodies-online Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 116. antibodies-online Recent Development
Table 117. ABclonal Technology Company Details
Table 118. ABclonal Technology Business Overview
Table 119. ABclonal Technology Anti-CD47 Antibody Product
Table 120. ABclonal Technology Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 121. ABclonal Technology Recent Development
Table 122. Abnova Corporation Company Details
Table 123. Abnova Corporation Business Overview
Table 124. Abnova Corporation Anti-CD47 Antibody Product
Table 125. Abnova Corporation Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 126. Abnova Corporation Recent Development
Table 127. G Biosciences Company Details
Table 128. G Biosciences Business Overview
Table 129. G Biosciences Anti-CD47 Antibody Product
Table 130. G Biosciences Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 131. G Biosciences Recent Development
Table 132. BioLegend Company Details
Table 133. BioLegend Business Overview
Table 134. BioLegend Anti-CD47 Antibody Product
Table 135. BioLegend Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 136. BioLegend Recent Development
Table 137. Bio-Rad Company Details
Table 138. Bio-Rad Business Overview
Table 139. Bio-Rad Anti-CD47 Antibody Product
Table 140. Bio-Rad Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 141. Bio-Rad Recent Development
Table 142. Huabio Company Details
Table 143. Huabio Business Overview
Table 144. Huabio Anti-CD47 Antibody Product
Table 145. Huabio Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 146. Huabio Recent Development
Table 147. BPS Bioscience Company Details
Table 148. BPS Bioscience Business Overview
Table 149. BPS Bioscience Anti-CD47 Antibody Product
Table 150. BPS Bioscience Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 151. BPS Bioscience Recent Development
Table 152. OriGene Technologies Company Details
Table 153. OriGene Technologies Business Overview
Table 154. OriGene Technologies Anti-CD47 Antibody Product
Table 155. OriGene Technologies Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 156. OriGene Technologies Recent Development
Table 157. St John's Laboratory Company Details
Table 158. St John's Laboratory Business Overview
Table 159. St John's Laboratory Anti-CD47 Antibody Product
Table 160. St John's Laboratory Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 161. St John's Laboratory Recent Development
Table 162. Absolute Antibody Company Details
Table 163. Absolute Antibody Business Overview
Table 164. Absolute Antibody Anti-CD47 Antibody Product
Table 165. Absolute Antibody Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 166. Absolute Antibody Recent Development
Table 167. NSJ Bioreagents Company Details
Table 168. NSJ Bioreagents Business Overview
Table 169. NSJ Bioreagents Anti-CD47 Antibody Product
Table 170. NSJ Bioreagents Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 171. NSJ Bioreagents Recent Development
Table 172. Cell Signaling Technology Company Details
Table 173. Cell Signaling Technology Business Overview
Table 174. Cell Signaling Technology Anti-CD47 Antibody Product
Table 175. Cell Signaling Technology Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 176. Cell Signaling Technology Recent Development
Table 177. RayBiotech Company Details
Table 178. RayBiotech Business Overview
Table 179. RayBiotech Anti-CD47 Antibody Product
Table 180. RayBiotech Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 181. RayBiotech Recent Development
Table 182. Beijing Solarbio Science & Technology Company Details
Table 183. Beijing Solarbio Science & Technology Business Overview
Table 184. Beijing Solarbio Science & Technology Anti-CD47 Antibody Product
Table 185. Beijing Solarbio Science & Technology Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 186. Beijing Solarbio Science & Technology Recent Development
Table 187. Bethyl Laboratories Company Details
Table 188. Bethyl Laboratories Business Overview
Table 189. Bethyl Laboratories Anti-CD47 Antibody Product
Table 190. Bethyl Laboratories Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 191. Bethyl Laboratories Recent Development
Table 192. Abeomics Company Details
Table 193. Abeomics Business Overview
Table 194. Abeomics Anti-CD47 Antibody Product
Table 195. Abeomics Revenue in Anti-CD47 Antibody Business (2021-2026) & (US$ Million)
Table 196. Abeomics Recent Development
Table 197. Anti-CD47 Antibody Market Trends
Table 198. Anti-CD47 Antibody Market Drivers
Table 199. Anti-CD47 Antibody Market Challenges
Table 200. Anti-CD47 Antibody Market Restraints
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources


List of Figures
Figure 1. Anti-CD47 Antibody Product Picture
Figure 2. Global Anti-CD47 Antibody Market Share by Type: 2025 vs 2032
Figure 3. Monoclonal Antibody Features
Figure 4. Polyclonal Antibody Features
Figure 5. Global Anti-CD47 Antibody Market Share by Application: 2025 vs 2032
Figure 6. Biotechnology
Figure 7. Medical
Figure 8. University
Figure 9. Others
Figure 10. Anti-CD47 Antibody Report Years Considered
Figure 11. Global Anti-CD47 Antibody Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 12. Global Anti-CD47 Antibody Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Anti-CD47 Antibody Market Share by Revenue, by Region: 2021 vs 2025
Figure 14. North America Anti-CD47 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 15. Europe Anti-CD47 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Asia-Pacific Anti-CD47 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Latin America Anti-CD47 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Middle East & Africa Anti-CD47 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Global Anti-CD47 Antibody Market Share by Players in 2025
Figure 20. Global Top Anti-CD47 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD47 Antibody as of 2025)
Figure 21. The Top 10 and 5 Players Market Share by Anti-CD47 Antibody Revenue in 2025
Figure 22. North America Anti-CD47 Antibody Market Share by Type (2021-2026)
Figure 23. North America Anti-CD47 Antibody Market Share by Application (2021-2026)
Figure 24. Europe Anti-CD47 Antibody Market Share by Type (2021-2026)
Figure 25. Europe Anti-CD47 Antibody Market Share by Application (2021-2026)
Figure 26. Asia-Pacific Anti-CD47 Antibody Market Share by Type (2021-2026)
Figure 27. Asia-Pacific Anti-CD47 Antibody Market Share by Application (2021-2026)
Figure 28. Latin America Anti-CD47 Antibody Market Share by Type (2021-2026)
Figure 29. Latin America Anti-CD47 Antibody Market Share by Application (2021-2026)
Figure 30. Middle East & Africa Anti-CD47 Antibody Market Share by Type (2021-2026)
Figure 31. Middle East & Africa Anti-CD47 Antibody Market Share by Application (2021-2026)
Figure 32. BosterBio Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 33. Leinco Technologies Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 34. Bioss Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 35. Novus Biologicals Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 36. Thermo Fisher Scientific Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 37. Biorbyt Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 38. Abbexa Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 39. Bio X Cell Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 40. GeneTex Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 41. R&D Systems Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 42. LSBio Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 43. MyBioSource Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 44. ProSci Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 45. antibodies-online Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 46. ABclonal Technology Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 47. Abnova Corporation Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 48. G Biosciences Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 49. BioLegend Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 50. Bio-Rad Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 51. Huabio Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 52. BPS Bioscience Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 53. OriGene Technologies Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 54. St John's Laboratory Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 55. Absolute Antibody Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 56. NSJ Bioreagents Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 57. Cell Signaling Technology Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 58. RayBiotech Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 59. Beijing Solarbio Science & Technology Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 60. Bethyl Laboratories Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 61. Abeomics Revenue Growth Rate in Anti-CD47 Antibody Business (2021-2026)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed